Search

• We integrate a PSO with a NN and ERNN to form PSO-NN and PSO-ERNN metaheuristic models. • The PSO trains the NN and ERNN to achieve faster convergence and avoid local minima. • The PSO-NN and PSO-ERNN models are evaluated using ten benchmark classification datasets. • The accuracy and computational efficiency of the models are improved. • The PSO-ERNN model outperforms the PSO-NN model for most of the tested datasets. There are several types of neural networks (NNs) that are widely used for data classification tasks. The supervised learning NN is an advanced network with a training algorithm for setting the weights and biases of the network in its training phase. However, traditional training algorithms such as backpropagation have some drawbacks, such as slow convergence speed and falling into local minima, which reduces the performance of the classifier. Therefore, different nature-inspired metaheuristic algorithms are integrated with the NN training algorithms to provide derivative-free solutions for complex classification problems. Consequently, this paper proposes the integration of a particle swarm optimization (PSO) algorithm with an improved Elman recurrent neural network (ERNN) to form a PSO-ERNN metaheuristic model. The key contribution of this study is the development of a new dimensional equation for ERNN architecture and the integration of PSO in ERNN learning to produce the PSO-ERNN model. The PSO is constructed to train the NN and ERNN models to achieve a fast convergence rate and avoid local minima problems. The PSO-ERNN model is validated by comparing it against the standard PSO-NN metaheuristic model and similar models from the literature. The PSO-NN and PSO-ERNN models are tested and evaluated using ten benchmark classification problems of breast cancer, heart, hepatitis, liver, wine, iris, lung cancer, yeast, Pima Indians diabetes, and ionosphere datasets. In the training phase, the results show that the PSO-ERNN model performs better than the PSO-NN model when the training set has a bigger size of samples. In the testing phase, the PSO-ERNN model outperforms the PSO-NN model for all the tested datasets except the lung cancer and yeast datasets, in which the accuracy percentage slightly decreases. In the validation phase, the PSO-ERNN model shows better performance quality in terms of accuracy percentage in six of the tested datasets. The average percentage of the training, testing, and validation accumulation show that the PSO-NN performs better than the PSO-ERNN in the lung cancer (87.27, 83.32), and heart (73.56, 70.64) datasets. On the other hand, the PSO-ERNN performs better than the PSO-NN in the iris (88.18, 86.74), hepatitis (88.60, 87.93), wine (89.16, 86.08), liver (73.56, 70.64), ionosphere (83.98, 78.94), and breast cancer (94.84, 91.17). PSO-NN and PSO-ERNN produce the same average results in the Pima Indians diabetes (84.00, 84.00) and yeast (91.31, 91.30) dataset. These results show clearly that the PSO-ERNN generally outperforms the PSO-NN when considering the overall results of the ten datasets. Nevertheless, the combinations of the PSO-NN and PSO-ERNN are proven to represent consistent and robust classification methods. The computational efficiencies of the training processes in both the PSO-NN and PSO-ERNN models are highly improved when coupled with the PSO. [ABSTRACT FROM AUTHOR]